Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] | U.S. Patent No. 7,404,956U.S. Patent No. 10,058,480U.S. Patent No. 10,588,949U.S. Patent No. 10,849,823 |
ALTUVIIIO®[Antihemophilic Factor (Recombinant),Fc-VWF-XTEN Fusion Protein-ehtl] | U.S. Patent No. 8,673,860U.S. Patent No. 9,371,369U.S. Patent No. 10,138,291U.S. Patent No. 10,421,798U.S. Patent No. 11,192,936U.S. Patent No. 11,370,827 |
Cablivi® (caplacizumab-yhdp) | U.S. Patent No. 7,807,162U.S. Patent No. 8,372,398U.S. Patent No. 10,035,862 |
Caprelsa® (vandetanib) Tablets | U.S. Patent No. 8,067,427 |
Cerdelga® (eliglustat) capsules | U.S. Patent No. 7,196,205U.S. Patent No. 11,458,119 |
Dupixent® (dupilumab) Injectionis a product in collaboration with Regeneron. | U.S. Patent No. 7,608,693U.S. Patent No. 8,735,095U.S. Patent No. 8,945,559U.S. Patent No. 9,238,692U.S. Patent No. 10,435,473U.S. Patent No. 11,059,896U.S. Patent No. 11,926,670 |
Eloctate® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] | U.S. Patent No. 7,404,956U.S. Patent No. 9,623,088U.S. Patent No. 10,058,480U.S. Patent No. 10,849,823 |
Jevtana® (cabazitaxel) Injection | U.S. Patent No. 7,241,907 |
Kevzara® (sarilumab) Injectionis a product in collaboration with Regeneron. | U.S. Patent No. 7,582,298U.S. Patent No. 8,183,014U.S. Patent No. 10,072,086U.S. Patent No. 11,098,127U.S. Patent No. 12,077,593 |
Nexviazyme® (avalglucosidase alfa-ngpt) | U.S. Patent No. 8,759,501 |
Qfitlia™ (fitusiran) injection | U.S. Patent No. 9,127,274U.S. Patent No. 9,376,680U.S. Patent No. 10,441,719U.S. Patent No. 10,471,210U.S. Patent No. 10,918,803U.S. Patent No. 10,918,811U.S. Patent No. 11,027,068U.S. Patent No. 11,045,610U.S. Patent No. 11,266,782U.S. Patent No. 11,400,216U.S. Patent No. 11,400,221U.S. Patent No. 11,400,222U.S. Patent No. 11,406,763U.S. Patent No. 11,406,764U.S. Patent No. 11,484,655U.S. Patent No. 11,541,188U.S. Patent No. 11,583,634 |
Rezurock® (belumosudil) tablets | U.S. Patent No. 8,357,693 |
Sarclisa® (isatuximab-irfc) | U.S. Patent No. 8,153,765 |
Soliqua® 100/33 (insulin glargine and lixisenatide)injection 100 Units/mL and 33 mcg/mL | U.S. Patent No. RE45,313U.S. Patent No. 9,526,764U.S. Patent No. 9,707,176U.S. Patent No. 9,717,852U.S. Patent No. 10,029,011U.S. Patent No. 10,117,909 |
Toujeo® (insulin glargine injection) 300 Units/mL | U.S. Patent No. 9,345,750U.S. Patent No. 10,369,291U.S. Patent No. 11,213,628U.S. Patent No. 11,376,365U.S. Patent No. 11,400,218 |
Zaltrap® (ziv-aflibercept) Injection for Intravenous Infusion | U.S. Patent No. 8,110,546U.S. Patent No. 8,710,004 |